Skip to main content
Be The Investor
ARKG

ARKG ETF

ARK Genomic Revolution ETF by ARK
GenomicsBiotechInnovationThematic ETF
$46.70
-2.54(-5.16%)
Latest available quote
AUM
$2.2B
Expense Ratio
0.75%
Dividend Yield
-
YTD Return
+60.04%
NAV
$46.64
Tracking Index
Actively Manage…
Volume
9.8M
Risk Level
High

ARK Genomic Revolution ETF (ARKG) Holdings

All ARK Genomic Revolution ETF (ARKG) holdings in one table: ticker, company, sector, weight and rank. See the top positions, sector concentration and diversification at a glance.

Total Holdings10
Top 10 Concentration58.4%
Largest HoldingTXG
Largest SectorHealthcare

Sector Allocation

Healthcare96.0%
Technology3.4%
Cash & Others0.7%
1TXG
TXG
10X GENOMICS INC-CLASS A
8.74%
2TEM
TEM
TEMPUS AI INC-CL A
8.62%
3TWST
TWST
TWIST BIOSCIENCE CORP
8.22%
4CRSP
CRSP
CRISPR THERAPEUTICS AG
5.59%
5NTRA
NTRA
NATERA INC
4.93%
6GH
GH
GUARDANT HEALTH INC
4.93%
7ILMN
ILMN
ILLUMINA INC
4.89%
8ABSI
ABSI
ABSCI CORP
4.64%
9LLY
LLY
ELI LILLY & CO
4.01%
10CDNA
CDNA
CAREDX INC
3.86%
11BEAM
BEAM
BEAM THERAPEUTICS INC
3.45%
12VCYT
VCYT
VERACYTE INC
3.40%
13RXRX
RXRX
RECURSION PHARMACEUTICALS-A
3.13%
14SDGR
SDGR
SCHRODINGER INC
2.82%
15CMPS
CMPS
COMPASS PATHWAYS PLC
2.80%
16NRIX
NRIX
NURIX THERAPEUTICS INC
2.77%
17ADPT
ADPT
ADAPTIVE BIOTECHNOLOGIES
2.30%
18PSNL
PSNL
PERSONALIS INC
2.03%
19BFLY
BFLY
BUTTERFLY NETWORK INC
1.90%
20IONS
IONS
IONIS PHARMACEUTICALS INC
1.90%
21WGS
WGS
GENEDX HOLDINGS CORP
1.78%
22ARCT
ARCT
ARCTURUS THERAPEUTICS HOLDIN
1.57%
23ALMR
ALMR
ALAMAR BIOSCIENCES INC
1.51%
24PRME
PRME
PRIME MEDICINE INC
1.38%
25MASS
MASS
908 DEVICES INC
1.15%
26PACB
PACB
PACIFIC BIOSCIENCES OF CALIF
1.06%
27GENB
GENB
GENERATE BIOMEDICINES INC
1.01%
28SCTX
SCTX
SCRIBE THERAPEUTICS INC
0.89%
29NTLA
NTLA
INTELLIA THERAPEUTICS INC
0.87%
30CERS
CERS
CERUS CORP
0.86%
31FRNM
FRNM
FREENOME INC
0.78%
32ARKG
ARKG
GOLDMAN FS TRSY OBLIG INST 468
0.67%
33IAM
IAM
IAMBIC THERAPEUTICS INC
0.56%
34KYMR
KYMR
KYMERA THERAPEUTICS INC
0.54%
35QSI
QSI
QUANTUM-SI INC
0.45%
Market data provided by third parties and may be delayed. Not investment advice. Past performance is not indicative of future results.